BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 38287839)

  • 21. Multipotent Mesenchymal Stromal Cells in Rheumatoid Arthritis and Systemic Lupus Erythematosus; From a Leading Role in Pathogenesis to Potential Therapeutic Saviors?
    El-Jawhari JJ; El-Sherbiny Y; McGonagle D; Jones E
    Front Immunol; 2021; 12():643170. PubMed ID: 33732263
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Metabolic reprogramming as a key regulator in the pathogenesis of rheumatoid arthritis.
    Cai WW; Yu Y; Zong SY; Wei F
    Inflamm Res; 2020 Nov; 69(11):1087-1101. PubMed ID: 32797249
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Alternative tumour necrosis factor inhibitors (TNFi) or abatacept or rituximab following failure of initial TNFi in rheumatoid arthritis: the SWITCH RCT.
    Brown S; Everett CC; Naraghi K; Davies C; Dawkins B; Hulme C; McCabe C; Pavitt S; Emery P; Sharples L; Buch MH
    Health Technol Assess; 2018 Jun; 22(34):1-280. PubMed ID: 29900829
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Lessons From the Success and Failure of Targeted Drugs for Rheumatoid Arthritis: Perspectives for Effective Basic and Translational Research.
    Kim M; Choe YH; Lee SI
    Immune Netw; 2022 Feb; 22(1):e8. PubMed ID: 35291656
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The effect of targeted rheumatoid arthritis therapies on anti-citrullinated protein autoantibody levels and B cell responses.
    Modi S; Soejima M; Levesque MC
    Clin Exp Immunol; 2013 Jul; 173(1):8-17. PubMed ID: 23607804
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The Role of Biologics in Rheumatoid Arthritis: A Narrative Review.
    Patel JP; Konanur Srinivasa NK; Gande A; Anusha M; Dar H; Baji DB
    Cureus; 2023 Jan; 15(1):e33293. PubMed ID: 36606106
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Rheumatoid arthritis: pathogenesis and therapeutic advances.
    Gao Y; Zhang Y; Liu X
    MedComm (2020); 2024 Mar; 5(3):e509. PubMed ID: 38469546
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Tocilizumab in the treatment of rheumatoid arthritis: an evidence-based review and patient selection.
    Biggioggero M; Crotti C; Becciolini A; Favalli EG
    Drug Des Devel Ther; 2019; 13():57-70. PubMed ID: 30587928
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Signaling pathways in rheumatoid arthritis: implications for targeted therapy.
    Ding Q; Hu W; Wang R; Yang Q; Zhu M; Li M; Cai J; Rose P; Mao J; Zhu YZ
    Signal Transduct Target Ther; 2023 Feb; 8(1):68. PubMed ID: 36797236
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Novel Therapeutic Approaches in Rheumatoid Arthritis: Role of Janus Kinases Inhibitors.
    Rivellese F; Lobasso A; Barbieri L; Liccardo B; de Paulis A; Rossi FW
    Curr Med Chem; 2019; 26(16):2823-2843. PubMed ID: 29424301
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The type I IFN system in rheumatoid arthritis.
    Conigliaro P; Perricone C; Benson RA; Garside P; Brewer JM; Perricone R; Valesini G
    Autoimmunity; 2010 Apr; 43(3):220-5. PubMed ID: 20166872
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Where do T cells stand in rheumatoid arthritis?
    Fournier C
    Joint Bone Spine; 2005 Dec; 72(6):527-32. PubMed ID: 16087382
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effects of Biological/Targeted Therapies on Bone Mineral Density in Inflammatory Arthritis.
    Chen TL; Chang KH; Su KY
    Int J Mol Sci; 2022 Apr; 23(8):. PubMed ID: 35456929
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Identification of biomarkers in patients with rheumatoid arthritis responsive to DMARDs but with progressive bone erosion.
    Marasco E; Fabbriciani G; Rotunno L; Longhi M; De Luca P; de Girolamo L; Colombini A
    Front Immunol; 2023; 14():1254139. PubMed ID: 37809106
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Biomaterial-based immunotherapeutic strategies for rheumatoid arthritis.
    Tu AB; Lewis JS
    Drug Deliv Transl Res; 2021 Dec; 11(6):2371-2393. PubMed ID: 34414564
    [TBL] [Abstract][Full Text] [Related]  

  • 36. PAPA Syndrome: Challenges in Achieving Long-Term Remission.
    Smajlović H; Prohić A
    Acta Dermatovenerol Croat; 2023 Nov; 31(2):106-109. PubMed ID: 38006373
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Rheumatoid arthritis: Biological therapy other than anti-TNF.
    Rossi D; Modena V; Sciascia S; Roccatello D
    Int Immunopharmacol; 2015 Aug; 27(2):185-8. PubMed ID: 25840282
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Metabolic Checkpoints in Rheumatoid Arthritis.
    Pucino V; Certo M; Varricchi G; Marone G; Ursini F; Rossi FW; De Paulis A; Mauro C; Raza K; Buckley CD
    Front Physiol; 2020; 11():347. PubMed ID: 32362840
    [TBL] [Abstract][Full Text] [Related]  

  • 39. JAK/STAT pathway in pathology of rheumatoid arthritis (Review).
    Ciobanu DA; Poenariu IS; Crînguș LI; Vreju FA; Turcu-Stiolica A; Tica AA; Padureanu V; Dumitrascu RM; Banicioiu-Covei S; Dinescu SC; Boldeanu L; Siloși I; Ungureanu AM; Boldeanu MV; Osiac E; Barbulescu AL
    Exp Ther Med; 2020 Oct; 20(4):3498-3503. PubMed ID: 32905201
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Vitamin D Deficiency and Rheumatoid Arthritis.
    Ishikawa LLW; Colavite PM; Fraga-Silva TFC; Mimura LAN; França TGD; Zorzella-Pezavento SFG; Chiuso-Minicucci F; Marcolino LD; Penitenti M; Ikoma MRV; Sartori A
    Clin Rev Allergy Immunol; 2017 Jun; 52(3):373-388. PubMed ID: 27484684
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.